When you read that clear clinical improvements have been observed in patients with severe neurological disease treated with GLPs
and neuro-ophthalmologists recognize GLPs as a rare and significant development in the ability to protect against and treat previously untreatable vision loss via its neuroprotective effects, it becomes clear the only thing holding back an expanded list of new clinical uses for GLPs is that research capacity is maxed out for the time being.
I was telling an elderly neighbor of mine, who didn't have coverage for Wegovy past the expiration of the manufacturers coupon despite, unfortunately, telling me how much better she felt on it, that I feel any delay in being able to get access to GLPs is really robbing from the potential of a significantly longer, and higher quality of life.
She's pretty tech savvy for her age though, maybe I'll give her QSC's contact info...